Kraig Biocraft Laboratories, Inc. Gears Up to Double the Number of Genetic Insertions Performed

LANSING, Mich., May 12, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) announce that the scientific team is preparing to significantly ramp up the number of genetic insertions performed in the month of May. The team anticipates that the rate of DNA construct insertions in May will be double that which has been performed to date.

“We are now entering the next phase in which the team is reallocating recourses to genetic insertion,” said CEO Kim Thompson.

“This is directly related to our recent development of new DNA constructs that are specifically targeted for the production of new fusion silk proteins. We intend to dramatically ramp up the number of insertions performed in order to gain the maximum benefit from the new insertion packets.”

Every targeted DNA packet insertion has the potential to create a new recombinant fiber with commercial applications.

Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company plans to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.


For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site:


This press release includes certain statements that may be deemed to be “forward-looking

statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.


CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

This entry was posted on by .